Patents Assigned to Ludwig Institute for Cancer Research Ltd.
-
Patent number: 10266894Abstract: This application discloses methods for cDN?A synthesis with improved reverse transcription, template switching and preamplification to increase both yield and average length of cDNA libraries generated from individual cells. The new methods include exchanging a single nucleoside residue for a locked nucleic acid (INA) at the TSO 3? end, using a methyl group donor, and/or a MgCb concentration higher than conventionally used. Single-cell transcriptome analyses incorporating these differences have full-length coverage, improved sensitivity and accuracy, have less bias and are more amendable to cost-effective automation. The invention also provides cDNA molecules comprising a locked nucleic acid at the 3?-end, compositions and cDNA libraries comprising these cDNA molecules, and methods for single-cell transcriptome profiling.Type: GrantFiled: August 22, 2014Date of Patent: April 23, 2019Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTDInventors: Rickard Sandberg, Simone Picelli, Omid R. Faridani
-
Patent number: 10259882Abstract: The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human OX40 and modulate OX40 activity, e.g., enhance, activate, or induce OX40 activity, or reduce, deactivate, or inhibit OX40 activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., enhances, activates, or induces OX40 activity. Also provided are methods for treating autoimmune or inflammatory diseases or disorders, by administering an antibody that specifically binds to human OX40 and modulates OX40 activity, e.g., reduces, deactivates, or inhibits OX40 activity.Type: GrantFiled: May 6, 2016Date of Patent: April 16, 2019Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research LtdInventors: Marc Van Dijk, Ekaterina V. Breous-Nystrom, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Nicholas S. Wilson
-
Publication number: 20190048063Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: July 30, 2018Publication date: February 14, 2019Applicants: Acceleron Pharma Inc., Ludwig Institute for Cancer Research Ltd.Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
-
Patent number: 10155818Abstract: The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human GITR and modulate GITR activity, e.g., enhance, activate or induce GITR activity, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as cancer and infectious diseases, by administering an antibody that specifically binds to human GITR and modulates GITR activity e.g., enhances, activates or induces GITR activity.Type: GrantFiled: May 28, 2015Date of Patent: December 18, 2018Assignees: Agenus Inc., Memorial Sloan-Kettering Cancer Center, Ludwig Institute for Cancer Research Ltd.Inventors: Volker Seibert, Olivier Léger, Marc Van Dijk, Taha Merghoub, David Schaer, Gerd Ritter, Takemasa Tsuji
-
Publication number: 20180346606Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.Type: ApplicationFiled: June 14, 2018Publication date: December 6, 2018Applicant: Ludwig Institute for Cancer Research Ltd.Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
-
Patent number: 10144779Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.Type: GrantFiled: May 27, 2016Date of Patent: December 4, 2018Assignees: AGENUS INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD, MEMORIAL SLOAN KETTERING CANCER CENTERInventors: Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
-
Publication number: 20180222984Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: ApplicationFiled: February 12, 2018Publication date: August 9, 2018Applicants: Ludwig Institute for Cancer Research Ltd, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 10039715Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.Type: GrantFiled: August 31, 2016Date of Patent: August 7, 2018Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Vincenzo Cerundolo, Simon Eastman
-
Patent number: 10035851Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: November 2, 2016Date of Patent: July 31, 2018Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Patent number: 10023657Abstract: Some aspects of this invention are based on the recognition that reversible protein multimers in which monomeric proteins are conjugated to a carrier molecule via chelation complex bonds are stable under physiological conditions and can be dissociated in a controlled manner under physiological, nontoxic conditions. Accordingly, such protein multimers are useful for a variety of in vitro, ex vivo, and in vivo application for research, diagnostics, and therapy. Some aspect of this invention provide reversible MHC protein multimers, and methods of using such multimers in the detection and/or isolation of specific T-cells or T-cell populations. Because reversible MHC multimers can efficiently be dissociated, the time of MHC binding to T-cell receptors, and, thus, T-cell receptor-mediated T-cell activation can be minimized.Type: GrantFiled: September 30, 2011Date of Patent: July 17, 2018Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Immanuel F. Luescher, Julien Schmidt, Philippe Guillaume, Danijel Dojcinovic
-
Patent number: 10023653Abstract: Expression of proteolytically active, high molecular weight ADAM protease is relatively increased in tumor cells that also express the putative tumor stem cell marker CD133. An antibody or antibody fragment such as 8C7 monoclonal antibody may be used to selectively bind to proteolytically active, high molecular weight ADAM10 protease to thereby detect tumor cells and also as a therapeutic agent for treating cancers, tumors and other malignancies inclusive of leukemia, lymphoma, lung cancer, colon cancer, adenoma, neuroblastoma, brain tumor, renal tumor, prostate cancer, sarcoma and/or melanoma.Type: GrantFiled: February 4, 2015Date of Patent: July 17, 2018Assignees: Monash University, Memorial Sloan-Kettering Cancer Centre, Ludwig Institute for Cancer Research Ltd.Inventors: Martin Lackmann, Peter W. Janes, Lakmali Atapattu Mudiyanselage, Andrew M. Scott, Dimitar B. Nikolov, Nayanendu Saha
-
Publication number: 20180179293Abstract: In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a ligand-binding portion of the extracellular domain of activin-like kinase I (ALK1) polypeptide may be used to inhibit angiogenesis in vivo, particularly in mammals suffering angiogenesis-related disorders. Additionally, the disclosure demonstrates that inhibitors of ALK1 may be used to increase pericyte coverage in vascularized tissues, including tumors and the retina. The disclosure also identifies ligands for ALK1 and demonstrates that such ligands have pro-angiogenic activity, and describes antibodies that inhibit receptor-ligand interaction.Type: ApplicationFiled: February 13, 2018Publication date: June 28, 2018Applicants: Ludwig Institute for Cancer Research Ltd., Acceleron Pharma, Inc.Inventors: Asya Grinberg, John Knopf, Robert S. Pearsall, Ravindra Kumar, Jasbir Seehra, Kristian Pietras
-
Patent number: 10000572Abstract: The present invention relates to an antibody binding to the transmembrane protein ‘glycoprotein A repetitions predominant’ (GARP) in the presence of TGF-? and uses thereof.Type: GrantFiled: August 1, 2014Date of Patent: June 19, 2018Assignees: UNIVERSITÉ CATHOLIQUE DE LOUVAIN, LUDWIG INSTITUTE FOR CANCER RESEARCH LTDInventors: Sophie Lucas, Pierre Coulie, Julia Cuende Villasur, Laure Dumoutier, Jean-Christophe Renauld
-
Patent number: 9957507Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.Type: GrantFiled: November 9, 2015Date of Patent: May 1, 2018Assignees: ALNYLAM PHARMACEUTICALS, INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Dinah Sah, Pamela Tan, Webster Cavenee, Frank Furnari, Maria del Mar Inda Perez, Rudy Bonavia
-
Patent number: 9926372Abstract: Methods and compositions for modulating blood-neural barrier (BNB) for the treatment of CNS conditions such as edema, and for increased drug delivery efficacy across the BNB. The present invention further relates to improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway. The inventive method and composition is particularly suitable for conjunctive therapy of ischemic stroke using tPA and an anti-PDGF-C antagonist or an anti-PDGFR-? antagonist.Type: GrantFiled: October 6, 2016Date of Patent: March 27, 2018Assignees: Ludwig Institute for Cancer Research Ltd, The Regents of the University of Michigan, University of Maryland, BaltimoreInventors: Ulf Eriksson, Linda Fredriksson, Daniel Lawrence, Enming Su, Manuel Yepes, Dudley Strickland
-
Patent number: 9880171Abstract: Described herein are methods of evaluating metastatic potential of a cancer based on the phosphorylation state and/or intracellular localization of iASPP. Therapeutic regimens designed based on the results of the diagnostic methods are also provided.Type: GrantFiled: March 1, 2013Date of Patent: January 30, 2018Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Xin Lu, Min Lu
-
Publication number: 20170105936Abstract: The invention provides liposomes containing nonglycosidic ceramides within their bilayers, and compositions thereof. These liposomes activate murine iNKT cells and induce dendritic cell (DC) maturation, both in vitro and in vivo at an efficacy that is comparable to their corresponding soluble nonglycosidic ceramides. Also provided are methods for treating diseases using the liposomes and compositions of the invention.Type: ApplicationFiled: August 31, 2016Publication date: April 20, 2017Applicant: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.Inventors: Vincenzo Cerundolo, Simon Eastman
-
Patent number: 9518112Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to transforming growth factor beta 1 (TGF-?1) are provided, particularly recognizing human and mouse TGF-?1 and not recognizing or binding TGF-?2 or TGF-?3. Particular antibodies are provided which specifically recognize and neutralize TGF-?1. These antibodies are useful in the diagnosis and treatment of conditions associated with activated or elevated TGF-?1, including cancer, and for modulating immune cells and immune response, including immune response to cancer or cancer antigens. The anti-TGF-?1 antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies hereof, including antibody 13A1, whose sequences are provided herein.Type: GrantFiled: March 6, 2013Date of Patent: December 13, 2016Assignee: Ludwig Institute for Cancer Research LTDInventors: Jacques Van Snick, Catherine Uyttenhove, Thierry Boon
-
Publication number: 20160194645Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.Type: ApplicationFiled: November 9, 2015Publication date: July 7, 2016Applicants: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD., ALNYLAM PHARMACEUTICALS, INC.Inventors: Dinah Sah, Pamela Tan, Webster Cavenee, Frank Furnari, Maria del Mar Inda Perez, Rudy Bonavia
-
Patent number: 9314515Abstract: Treatments for estrogen receptor and progesterone receptor negative breast cancer or estrogen receptor, progesterone receptor and c-erbB2 negative (triple negative) breast cancer are provided.Type: GrantFiled: April 22, 2009Date of Patent: April 19, 2016Assignee: Ludwig Institute for Cancer Research Ltd.Inventors: Anita Grigoriadis, Otavia L. Caballero, Andrew John George Simpson